These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6804290)

  • 61. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture.
    Nagarajan T; Reddy GS; Mohana Subramanian B; Rajalakshmi S; Thiagarajan D; Tordo N; Jallet C; Srinivasan VA
    Biologicals; 2006 Mar; 34(1):21-7. PubMed ID: 16188454
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Marker studies of poliovirus.
    Cossart YE
    Nature; 1966 Sep; 211(5056):1432. PubMed ID: 4291100
    [No Abstract]   [Full Text] [Related]  

  • 63. Importance of experiments in poliovirus-susceptible transgenic mice for evaluating current potency tests of inactivated polio vaccine (IPV).
    Taffs R; Dragunsky E; Nomura T; Hioki K; Levenbook I; Fitzgerald E
    Dev Biol Stand; 1996; 86():345. PubMed ID: 8785985
    [No Abstract]   [Full Text] [Related]  

  • 64. A comparison of three methods for titration of poliovirus vaccines.
    Bey E; Golombick T
    J Virol Methods; 1984 Oct; 9(2):123-30. PubMed ID: 6096387
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New assays for the quality control of live oral poliovirus vaccine.
    Furesz J; Levenbook I
    Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunoglobulin a as a serological marker for the (silent) circulation of poliovirus in an inactivated poliovirus-vaccinated population.
    Herremans T; Kimman TG; Conyn-Van Spaendonck MA; Buisman A; de Melker H; Abbink F; Bijkerk P; Koopmans MP
    Clin Infect Dis; 2002 Apr; 34(8):1067-75. PubMed ID: 11914995
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sucrose density gradient centrifugation and cross-flow filtration methods for the production of arbovirus antigens inactivated by binary ethylenimine.
    Pyke AT; Phillips DA; Chuan TF; Smith GA
    BMC Microbiol; 2004 Jan; 4():3. PubMed ID: 14720306
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells.
    Prikazsky V; Leroux-Roels G; Van Damme P; Safary A; Colau B; Duchene M
    Vaccine; 2005 Jul; 23(33):4219-27. PubMed ID: 15936120
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development of pertussis serological potency test. Serological assessment of antibody response induced by whole cell vaccine as an alternative to mouse protection in an intracerebral challenge model.
    van der Ark A; van Straaten-van de Kappelle I; Akkermans A; Hendriksen C; van de Donk H
    Biologicals; 1994 Sep; 22(3):233-42. PubMed ID: 7811457
    [TBL] [Abstract][Full Text] [Related]  

  • 70. WHO activities towards the three Rs in the development and control of biological products.
    Milstien J; Grachev V; Padilla A; Griffiths E
    Dev Biol Stand; 1996; 86():31-9. PubMed ID: 8785961
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analysis of an in vivo assay for inactivated polio vaccine.
    Heath AB
    Dev Biol (Basel); 2002; 107():95-104. PubMed ID: 12079197
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Observations of the incidence of structural abnormalities in the chromosomes of WI-38 cells prepared for vaccine manufacture.
    Allnutt BJ; Purnell DJ; Roberts B
    Dev Biol Stand; 1976 Dec 13-15; 37():177-80. PubMed ID: 1031683
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Seroconversion after vaccination against pertussis, Haemophilus influenzae type b and poliomyelitis in preterm infants].
    Sikora JP; Chlebna-Sokół D
    Przegl Lek; 2003; 60(11):699-703. PubMed ID: 15058036
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influence of temperature on D-antigen and potency in chickens of inactivated poliomyelitis vaccines.
    van Ramshorst JD; Hofman B; Boere J
    Arch Gesamte Virusforsch; 1969; 26(1):11-20. PubMed ID: 4977292
    [No Abstract]   [Full Text] [Related]  

  • 76. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Determination of poliovirus-specific IgA in saliva by ELISA tests.
    Ivanov A; Dragunsky E; Ivanova O; Rezapkin G; Potapova S; Chumakov K
    J Virol Methods; 2005 Jun; 126(1-2):45-52. PubMed ID: 15847918
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Some lots of "Salk" vaccine have lost potency.
    FDA Drug Bull; 1984 Dec; 14(3):22-3. PubMed ID: 6526170
    [No Abstract]   [Full Text] [Related]  

  • 80. Storage of poliovirus vaccine.
    Chao J
    Am Fam Physician; 1991 Sep; 44(3):756, 758. PubMed ID: 1877422
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.